Vantage Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Vantage Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$1K	Hold	572	–	–	﹤0.01%	730
2018 Q2	$1K	Hold	572	–	–	﹤0.01%	728
2018 Q1	$1K	Hold	572	–	–	﹤0.01%	774
2017 Q4	$1K	Hold	572	–	–	﹤0.01%	791
2017 Q3	$1K	Hold	572	–	–	﹤0.01%	769
2017 Q2	$2K	Hold	572	–	–	﹤0.01%	709
2017 Q1	$2K	Hold	572	–	–	﹤0.01%	703
2016 Q4	$2K	Hold	572	–	–	﹤0.01%	709
2016 Q3	$2K	Hold	572	–	–	﹤0.01%	693
2016 Q2	$1K	Hold	572	–	–	﹤0.01%	772
2016 Q1	$1K	Sell	572 -48	-8%	-$107	﹤0.01%	762
2015 Q4	$2K	Hold	620	–	–	﹤0.01%	700
2015 Q3	$2K	Hold	620	–	–	﹤0.01%	708
2015 Q2	$2K	Sell	620 -619	-50%	-$2.4K	﹤0.01%	685
2015 Q1	$5K	Buy	1,239 +619	+100%	+$2.14K	﹤0.01%	686
2014 Q4	$2K	Hold	620	–	–	﹤0.01%	703
2014 Q3	$2K	Hold	620	–	–	﹤0.01%	655
2014 Q2	$2K	Hold	620	–	–	﹤0.01%	649
2014 Q1	$2K	Hold	620	–	–	﹤0.01%	606
2013 Q4	$2K	Buy	+620	New	+$1.87K	﹤0.01%	582

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vantage Investment Advisors's LCTX Position: Q3 2018 in Review

Vantage Investment Advisors held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2018 at 572 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #730.

Vantage Investment Advisors first reported a position in LCTX in Q4 2013 and has held it in 20 quarters since. The position peaked at $5K in Q1 2015. 106 funds tracked by Wall St. Rank hold LCTX as of Q3 2018.

Vantage Investment Advisors held 572 shares of Lineage Cell Therapeutics worth $1K as of Q3 2018.
Vantage Investment Advisors left its Lineage Cell Therapeutics share count unchanged in Q3 2018.
Lineage Cell Therapeutics made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #730 holding.
Vantage Investment Advisors first reported a position in Lineage Cell Therapeutics in Q4 2013 and has held it in 20 quarters since.
Vantage Investment Advisors's Lineage Cell Therapeutics position peaked at $5K in Q1 2015.
106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.